Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed an acceleration of the public health crisis in its key markets of France, Germany and Brazil. The company’s Novastep foot and ankle business posted nearly +31% growth for the quarter, and over 60% growth in the U.S.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q21
3Q20
$ Chg
% Chg
Joint Replacement
$27.8
$27.7
$0.2
0.7%
Knees
$16.0
$16.2
($0.2)
(1.5%)
Hips
$11.9
$11.4
$0.4
3.7%
Trauma
$4.1
$3.2
$1.0
30.8%
Sports Medicine
$1.0
$1.0
$0.0
0.2%
Orthobiologics
$0.7
$0.6
$0.1
7.9%
Total
$33.7
$32.5
$1.2
3.7%
9m21
9m20
$ Chg
% Chg
Joint Replacement
$74.2
$79.6
($5.4)
(6.8%)
Knees
$43.0
$46.8
($3.8)
(8.1%)
Hips
$31.2
$32.8
($1.6)
(5%)
Trauma
$11.6
$9.0
$2.6
28.4%
Sports Medicine
$2.4
$2.8
($0.4)
(13.4%)
Orthobiologics
$1.5
$1.9
($0.3)
(18.3%)
Total
$89.7
$93.3
($3.6)
(3.8%)
Geographic Sales
3Q21
3Q20
$ Chg
% Chg
France
$22.9
$21.6
$1.3
5.9%
International
$10.8
$10.9
($0.1)
(0.8%)
Subsidiaries
$8.2
$7.6
$0.6
8.1%
Distributors
$2.5
$3.2
($0.7)
(21.7%)
Total
$33.7
$32.5
$1.2
3.7%
9m21
9m20
$ Chg
% Chg
France
$59.0
$58.7
$0.3
0.6%
International
$30.6
$34.6
($3.9)
(11.3%)
Subsidiaries
$23.4
$25.2
($1.7)
(6.8%)
Distributors
$7.2
$9.4
($2.2)
(23.4%)
Total
$89.7
$93.3
($3.6)
(3.8%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed...
Amplitude Surgical reported FY 3Q21 orthopedic revenue of USD $33.7 million, +3.7% vs. 3Q20. Compared to FY 3Q19, the pre-pandemic period ending in March 2019, sales declined -6.4%.
The company continues dealing with the fallout of COVID’s third wave and resulting surgical restrictions. In the first half of April 2020, Amplitude observed an acceleration of the public health crisis in its key markets of France, Germany and Brazil. The company’s Novastep foot and ankle business posted nearly +31% growth for the quarter, and over 60% growth in the U.S.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q21
3Q20
$ Chg
% Chg
Joint Replacement
$27.8
$27.7
$0.2
0.7%
Knees
$16.0
$16.2
($0.2)
(1.5%)
Hips
$11.9
$11.4
$0.4
3.7%
Trauma
$4.1
$3.2
$1.0
30.8%
Sports Medicine
$1.0
$1.0
$0.0
0.2%
Orthobiologics
$0.7
$0.6
$0.1
7.9%
Total
$33.7
$32.5
$1.2
3.7%
9m21
9m20
$ Chg
% Chg
Joint Replacement
$74.2
$79.6
($5.4)
(6.8%)
Knees
$43.0
$46.8
($3.8)
(8.1%)
Hips
$31.2
$32.8
($1.6)
(5%)
Trauma
$11.6
$9.0
$2.6
28.4%
Sports Medicine
$2.4
$2.8
($0.4)
(13.4%)
Orthobiologics
$1.5
$1.9
($0.3)
(18.3%)
Total
$89.7
$93.3
($3.6)
(3.8%)
Geographic Sales
3Q21
3Q20
$ Chg
% Chg
France
$22.9
$21.6
$1.3
5.9%
International
$10.8
$10.9
($0.1)
(0.8%)
Subsidiaries
$8.2
$7.6
$0.6
8.1%
Distributors
$2.5
$3.2
($0.7)
(21.7%)
Total
$33.7
$32.5
$1.2
3.7%
9m21
9m20
$ Chg
% Chg
France
$59.0
$58.7
$0.3
0.6%
International
$30.6
$34.6
($3.9)
(11.3%)
Subsidiaries
$23.4
$25.2
($1.7)
(6.8%)
Distributors
$7.2
$9.4
($2.2)
(23.4%)
Total
$89.7
$93.3
($3.6)
(3.8%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
